JPM 2022: Abbott, iRhythm, Novocure, Zimmer Biomet

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the second day of the meeting.

J.P. Morgan Daily Notebook 2022 Day 2
• Source: Alamy

Abbott expects demand for its rapid COVID-19 tests to remain high through at least 2022, even if the current Omicron surge recedes.

During a “fireside chat” at the J.P. Morgan Healthcare Conference, Abbott CEO Robert Ford recalled that, early in the pandemic,...

More from Financing

More from Business